Based on evidence of SCFAs and neurodegenerative diseases, butyric acid has been implicated as a therapeutic candidate because of its ability to correct the disrupted activity of HDAC, which could mediate dopaminergic neuron death in PD23–25. The gene discussed is HDAC9; the disease is neurodegenerative disease.